“We are enthusiastic about Courier’s proprietary cell-targeting technology because we believe it positions Valo to create a new frontier in cancer-immunotherapies,” said David Berry, Valo CEO.
“This acquisition provides Valo with a unique opportunity to expand our proprietary capabilities into protein therapeutics, thereby extending our modalities and our reach while enabling us to potentially pioneer precision immune modulation as a tool against important diseases such as cancer.”
